ES2526648T3 - Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno - Google Patents
Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno Download PDFInfo
- Publication number
- ES2526648T3 ES2526648T3 ES08799127.9T ES08799127T ES2526648T3 ES 2526648 T3 ES2526648 T3 ES 2526648T3 ES 08799127 T ES08799127 T ES 08799127T ES 2526648 T3 ES2526648 T3 ES 2526648T3
- Authority
- ES
- Spain
- Prior art keywords
- oxidative stress
- working memory
- improve oxidative
- subject
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/075—Ethers or acetals
- A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
- A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/07—Retinol compounds, e.g. vitamin A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/45—Ericaceae or Vacciniaceae (Heath or Blueberry family), e.g. blueberry, cranberry or bilberry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Composición farmacéutica que contiene una cantidad terapéutica efectiva de pteroestilbeno sustancialmente puro de fórmula:**Fórmula** y un vehículo fisiológicamente aceptable, para emplearla en el tratamiento de déficits motores y/o enfermedades neurodegenerativas, incrementando la actividad receptora de acetilcolina en el sujeto mediante la administración de una cantidad de pteroestilbeno comprendida aproximadamente entre 2,5 mg y 10 mg por kilogramo de peso corporal del sujeto.
Description
Claims (1)
-
imagen1
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US97059107P | 2007-09-07 | 2007-09-07 | |
US970591P | 2007-09-07 | ||
US136341 | 2008-06-10 | ||
US12/136,341 US20090069444A1 (en) | 2007-09-07 | 2008-06-10 | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
PCT/US2008/075170 WO2009032870A2 (en) | 2007-09-07 | 2008-09-04 | Method to ameliorate oxidative stress and improve working memory via pterostilbene administration |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2526648T3 true ES2526648T3 (es) | 2015-01-14 |
Family
ID=40429677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08799127.9T Active ES2526648T3 (es) | 2007-09-07 | 2008-09-04 | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno |
Country Status (11)
Country | Link |
---|---|
US (3) | US20090069444A1 (es) |
EP (1) | EP2200597B1 (es) |
JP (1) | JP5608082B2 (es) |
KR (1) | KR20100075468A (es) |
CN (2) | CN103083288B (es) |
AU (1) | AU2008296293A1 (es) |
BR (1) | BRPI0816317A2 (es) |
CA (1) | CA2698661C (es) |
ES (1) | ES2526648T3 (es) |
HK (2) | HK1148932A1 (es) |
WO (1) | WO2009032870A2 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090069444A1 (en) * | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
EP2445488B1 (en) * | 2009-06-22 | 2020-03-18 | Indus Biotech Private Limited | Process for obtaining purified pterostilbene and methods of use thereof |
US20100119499A1 (en) * | 2009-09-17 | 2010-05-13 | Kneller Bruce W | Stilbene-based compositions and methods of use therefor |
US20110280850A1 (en) * | 2010-05-12 | 2011-11-17 | Starr Elizabeth I | Compositions Containing DNA Repair Enzyme And Anogeissus Extract |
US20120237494A1 (en) * | 2010-09-30 | 2012-09-20 | Daly Susan M | Compositions Containing Zinc PCA And Anogeissus Extract |
EP2537513A3 (en) * | 2011-03-11 | 2015-04-29 | ELC Management LLC | Use of anogeissus extract for fibrillin production in skin |
US9439875B2 (en) * | 2011-05-11 | 2016-09-13 | The United States Of America, As Represented By The Secretary Of Agriculture | Anxiolytic effect of pterostilbene |
US20130072509A1 (en) * | 2011-09-15 | 2013-03-21 | ChromaDex Inc. | Pterostilbene and statin combination for treatment of metabolic disease, cardiovascular disease, and inflammation |
JP6155191B2 (ja) * | 2011-10-02 | 2017-06-28 | キユーピー株式会社 | RNA干渉によるmRNA発現の抑制を促進する促進剤およびその用途 |
JP5901547B2 (ja) | 2012-03-28 | 2016-04-13 | 富士フイルム株式会社 | 組成物、これを含む皮膚外用剤、又は機能性食品 |
EP3063163B1 (en) | 2013-10-30 | 2022-08-10 | Chromadex Inc. | Nicotinamide riboside compositions for topical use in treating skin conditions |
WO2017011318A1 (en) | 2015-07-10 | 2017-01-19 | University Of Miami | Methods for treating mucopolysaccharidosis |
CA3034673A1 (en) | 2016-08-22 | 2018-03-01 | Elysium Health, Inc. | Nicotinamide riboside and pterostilbene compositions and methods for treatment of neurodegenerative disorders |
US9975915B1 (en) | 2016-11-11 | 2018-05-22 | The Queen's University Of Belfast | Crystalline forms of nicotinoyl ribosides, modified derivatives thereof, and phosphorylated analogs thereof, and methods of preparation thereof |
US11071747B2 (en) | 2016-11-29 | 2021-07-27 | University Of Iowa Research Foundation | Use of NAD precursors for breast enhancement |
JP7136795B2 (ja) | 2016-11-29 | 2022-09-13 | ユニバーシティー オブ アイオワ リサーチ ファウンデーション | 母体の健康および/または子の健康を向上させるためのnad前駆体の使用 |
KR20200144125A (ko) | 2018-05-15 | 2020-12-28 | 알카헤스트 인코포레이티드 | 류코트리엔 a4 가수분해효소의 조정제를 이용한 노화-연관 질환의 치료 |
JP7345312B2 (ja) * | 2019-08-09 | 2023-09-15 | キユーピー株式会社 | 発酵乳 |
CN112618520A (zh) * | 2021-01-14 | 2021-04-09 | 姚大纯 | 紫檀芪或白藜芦醇在制备用于治疗或改善孤独症谱系障碍的药物中的应用 |
CA3221177A1 (en) | 2021-11-01 | 2023-05-04 | Meghan Kerrisk Campbell | Benzodioxane modulators of leukotriene a4 hydrolase (lta4h) for prevention and treatment of aging-associated diseases |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050038125A1 (en) * | 2003-08-15 | 2005-02-17 | Smit Hobbe Friso | Method for the treatment of arthritis and pain |
JP4633572B2 (ja) * | 2004-07-30 | 2011-02-16 | イスクラ産業株式会社 | 糖尿病改善剤 |
US20060057231A1 (en) * | 2004-08-19 | 2006-03-16 | Rimando Agnes M | Pterostilbene as a new agonist for the peroxisome proliferator-activated receptor alpha isoform |
US20090069444A1 (en) * | 2007-09-07 | 2009-03-12 | The United States Of America, As Represented By Th E Secretary Of Agriculture | Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration |
-
2008
- 2008-06-10 US US12/136,341 patent/US20090069444A1/en not_active Abandoned
- 2008-09-04 EP EP20080799127 patent/EP2200597B1/en active Active
- 2008-09-04 CN CN201210421008.6A patent/CN103083288B/zh active Active
- 2008-09-04 BR BRPI0816317A patent/BRPI0816317A2/pt not_active IP Right Cessation
- 2008-09-04 JP JP2010524125A patent/JP5608082B2/ja active Active
- 2008-09-04 WO PCT/US2008/075170 patent/WO2009032870A2/en active Application Filing
- 2008-09-04 CN CN2008801103188A patent/CN101820869B/zh active Active
- 2008-09-04 ES ES08799127.9T patent/ES2526648T3/es active Active
- 2008-09-04 KR KR20107007002A patent/KR20100075468A/ko active Search and Examination
- 2008-09-04 CA CA2698661A patent/CA2698661C/en active Active
- 2008-09-04 AU AU2008296293A patent/AU2008296293A1/en not_active Abandoned
-
2011
- 2011-02-22 HK HK11101728A patent/HK1148932A1/xx unknown
- 2011-08-08 US US13/204,891 patent/US8809400B2/en active Active
-
2013
- 2013-11-08 HK HK13112566.4A patent/HK1185257A1/zh unknown
-
2014
- 2014-05-22 US US14/284,901 patent/US9028887B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN101820869A (zh) | 2010-09-01 |
JP5608082B2 (ja) | 2014-10-15 |
CN103083288A (zh) | 2013-05-08 |
HK1185257A1 (zh) | 2014-02-14 |
CA2698661C (en) | 2016-03-29 |
US20090069444A1 (en) | 2009-03-12 |
CA2698661A1 (en) | 2009-03-12 |
EP2200597B1 (en) | 2014-11-12 |
HK1148932A1 (en) | 2011-09-23 |
CN101820869B (zh) | 2012-12-12 |
KR20100075468A (ko) | 2010-07-02 |
WO2009032870A3 (en) | 2009-05-22 |
EP2200597A4 (en) | 2010-09-08 |
AU2008296293A1 (en) | 2009-03-12 |
US20120035272A1 (en) | 2012-02-09 |
EP2200597A2 (en) | 2010-06-30 |
US9028887B2 (en) | 2015-05-12 |
WO2009032870A2 (en) | 2009-03-12 |
JP2010538077A (ja) | 2010-12-09 |
US8809400B2 (en) | 2014-08-19 |
US20140256827A1 (en) | 2014-09-11 |
CN103083288B (zh) | 2016-04-13 |
BRPI0816317A2 (pt) | 2017-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2526648T3 (es) | Método para mejorar el estrés oxidativo y la memoria de trabajo mediante la administración de pterostilbeno | |
CO6160321A2 (es) | Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo | |
NI201100100A (es) | Moduladores de aril metil benzoquinazolinona alostéricos positivos del receptor m1. | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
ES2916604T1 (es) | Ensayos de detección de nrf2 y métodos y composiciones relacionados | |
RU2013111077A (ru) | Дипептидное пролекарство, его применение и лекарственное средство | |
PE20040134A1 (es) | Forma de dosificacion de una vez al dia de pramipexol | |
AR070047A1 (es) | Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog. | |
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
PE20040121A1 (es) | Formulaciones farmaceuticas de liberacion controlada del 5,8,14-triazatetraciclo [10.3.1.02,11.04.9]-hexadeca-2-(11),3,5,7,9-pentaeno | |
PE20120654A1 (es) | Formulaciones de 4-amino-2-(2,6-dioxopiperidin-1,3-il) isoindolin-1,3-diona | |
DOP2005000039A (es) | Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos | |
AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
AR062659A1 (es) | Composicion de liberacion sostenida de levodopa y metodo para su uso | |
AR082803A1 (es) | Metodos y formulaciones para el tratamiento de la trombosis con betrixaban y un inhibidor de la glicoproteina p | |
AR087744A1 (es) | Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa | |
CO6270217A2 (es) | Formulaciones galenicas de alisquireno y valsartan | |
JP2012508256A5 (es) | ||
AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
AR043259A1 (es) | Metodo para el tratamiento de insuficiencia cardiaca severa y medicamento para ello | |
AR036312A1 (es) | Composicion farmaceutica | |
ECSP077843A (es) | Tratamiento o prevención del prurito | |
AR061233A1 (es) | Formulacion de liberacion prolongada de naltrexona | |
UY31768A (es) | Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre |